Table 2 Pathological measures stratified according to APOE and CTSD genotypes and alleles, separately and in combination.
| Aβ40 | Aβ42 | CAA | ||||
|---|---|---|---|---|---|---|
| APOE genotype | ||||||
| e2/e2 (1) | 1.2 | 15.2 | 9.0 | |||
| e2/e3 (8) | 2.2 (1.7) | 10.2 (5.4) | 6.3 (1.5) | |||
| e2/e4 (2) | 5.4 (2.4) | 11.2 (0.7) | 6.5 (3.5) | |||
| e3/e3 (48) | 2.2 (2.2) | 9.6 (4.9) | 7.3 (2.5) | |||
| e3/e4 (60) | 3.2 (2.7) | 9.8 (5.3) | 7.1 (3.1) | |||
| e4/e4 (27) | 7.8 (5.0) | 9.8 (3.1) | 8.7 (2.8) | |||
| e4− (57) | 2.1 (2.1) | 9.8 (5.0) | 7.3 (2.4) | |||
| e4+ (89) | 4.5 (4.0) | 9.8 (4.7) | 7.5 (3.1) | |||
| CTSD genotype | ||||||
| CC (127) | 3.3 (3.2) | 9.7 (4.8) | 7.5 (2.9) | |||
| CT (19) | 5.9 (5.2) | 10.5 (4.1) | 7.1 (2.4) | |||
| APOE/CTSD combination | ||||||
| e4− T− (77) | 2.1 (2.0) | 9.4 (4.8) | 7.4 (2.4) | |||
| e4− T+ (6) | 3.8 (2.5) | 12.0 (5.5) | 6.5 (3.1) | |||
| e4+ T− (50) | 4.1 (3.5) | 9.8 (4.9) | 7.6 (3.2) | |||
| e4+ T+ (13) | 7.0 (5.9) | 9.7 (3.3) | 7.3 (2.2) | |||
Data are means (SD).